Dorsal root ganglia (DRG), trigeminal ganglia (TG), other sensory ganglia, and autonomic
ganglia may be injured by some test article classes, including anti-neoplastic …

Adeno-associated virus (AAV)-based vectors are the most frequently used platform for
retinal gene therapy. Initially explored for the treatment of loss-of-function mutations …

Dorsal root ganglion (DRG) toxicity has been consistently reported as a potential safety
concern after delivery of adeno-associated viruses (AAVs) containing gene-replacement …

Biotherapeutic modalities such as cell therapies, gene therapies, nucleic acids, and proteins
are increasingly investigated as disease-modifying treatments for severe and life …

Adeno-associated virus (AAV) gene therapy vectors are an accepted platform for treating
severe neurological diseases. Test article (TA)-related and procedure-related …

Existing nervous system sampling and processing “best practices” for nonclinical general
toxicity studies (GTS) were designed to assess test articles with unknown, no known, or well …

Direct delivery of therapeutics to the central nervous system (CNS) greatly expands
opportunities to treat neurological diseases but is technically challenging. This opinion …